The DOI matches its Crossref record; 158 of the 159 references it cites were found in a registry or an index.
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Abstract
Tissue hypoxia results from an inadequate supply of oxygen (O(2)) that compromises biologic functions. Evidence from experimental and clinical studies increasingly points to a fundamental role for hypoxia in solid tumors. Hypoxia in tumors is primarily a pathophysiologic consequence of structurally and functionally disturbed microcirculation and the deterioration of diffusion conditions. Tumor hypoxia appears to be strongly associated with tumor propagation, malignant progression, and resistance to therapy, and it has thus become a central issue in tumor physiology and cancer treatment. Biochemists and clinicians (as well as physiologists) define hypoxia differently; biochemists define it as O(2)-limited electron transport, and physiologists and clinicians define it as a state of reduced O(2) availability or decreased O(2) partial pressure that restricts or even abolishes functions of organs, tissues, or cells. Because malignant tumors no longer execute functions necessary for homeostasis (such as the production of adequate amounts of adenosine triphosphate), the physiology-based definitions of the term "hypoxia" are not necessarily valid for malignant tumors. Instead, alternative definitions based on clinical, biologic, and molecular effects that are observed at O(2) partial pressures below a critical level have to be applied.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Radiobiology for the Radiologist.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-3-438_1 · Cited by 3,498
(1989) · PubMed · Cited by 3,343
Self-citationHypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
Holmgren, L., O’Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,891
HIF-1: mediator of physiological and pathophysiological responses to hypoxia
Semenza, G. L. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1474 · Cited by 1,822
Höckel, M., Schlenger, K., Aral, B., Mitze, M., Schäffer, U., & Vaupel, P. W. (1996) · PubMed · Cited by 1,727
Self-citation
Research works printed but not linked: 35
- Brown, 1998, Cancer Research, 58, 1408
- Hockel, 1996, Cancer Research, 56, 4509
- Brizel, 1996, Cancer Research, 56, 941
- Walenta, 2000, Cancer Research, 60, 916
- Hockel, 1999, Cancer Research, 59, 4525
- Kim, 1997, Cancer Research, 57, 4200
- Anthoney, 1996, Cancer Research, 56, 1374
- Vaupel, 1989, Cancer Research, 49, 6449
- Vaupel, 1987, Cancer Research, 47, 3496
- Kallinowski, 1989, Cancer Research, 49, 3759
- 1973, Advances in experimental medicine and biology, 37, 277
- Vaupel, 1991, Cancer Research, 51, 3316
- Hockel, 1991, Cancer Research, 51, 6098
- Wilson, 1992, Cancer Research, 52, 3988
- 1996, BRITISH JOURNAL OF CANCER, 74, S226
- Valk, 1992, Journal of Nuclear Medicine, 33, 2133
- Groshar, 1993, Journal of Nuclear Medicine, 34, 885
- Lord, 1993, Cancer Research, 53, 5721
- Evans, 1996, Cancer Research, 56, 405
- Riva, 1998, Anticancer Research, 18, 4729
- Prehn, 1991, Cancer Research, 51, 2
- Ausserer, 1994, Molecular and Cellular Biology, 14, 5032, 10.1128/mcb.14.8.5032 · DOI
- Hartmann, 1999, Cancer Research, 59, 1578
- Koong, 1994, Cancer Research, 54, 1425
- Henderson, 1987, Cancer Research, 47, 3110
- Mitchell, 1985, Cancer Research, 45, 2008
- Reynolds, 1996, Cancer Research, 56, 5754
- Stoler, 1992, Cancer Research, 52, 4372
- Russo, 1995, Cancer Research, 55, 1122
- Teicher, 1990, Cancer Research, 50, 3339
- Teicher, 1981, Cancer Research, 41, 73
- Moan, 1985, Cancer Research, 45, 1608
- 1981, Bibliotheca anatomica, 20, 628
- 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 46, S107
- 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 48, S162
Cited by
Sorted by citations
Items 1,001–1,008 of 1,008
Pang, Y., Yang, C., Schovanek, J., Wang, H., Bullova, P., Caisova, V., Gupta, G., Wolf, K. I., Semenza, G. L., Zhuang, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16224 · Cited by 37
Jarrar, Y., Zihlif, M., Al Bawab, A. Q., & Sharab, A. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009619666191116095847 · Cited by 36
Myc-induced glutaminolysis bypasses HIF-driven glycolysis in hypoxic small cell lung carcinoma cells
Thorén, M. M., Vaapil, M., Staaf, J., Planck, M., Johansson, M. E., Mohlin, S., & Påhlman, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16904 · Cited by 31
“Tumors are generally poorly oxygenated due to high tumor cell proliferation rate and incomplete vascularization [1, 2].”
BackgroundTumors exposed to acute cyclic hypoxia show increased vessel density and delayed blood supply
Gaustad, J.-V., Simonsen, T. G., Roa, A. M. A., & Rofstad, E. K. (2013) · Microvascular Research · doi:10.1016/j.mvr.2012.11.002 · Cited by 20
Dou, Y. N., Chaudary, N., Chang, M. C., Dunne, M., Huang, H., Jaffray, D. A., Milosevic, M., & Allen, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.039 · Cited by 21
Lee, H. Y., Kim, I. K., Lee, H. I., Lee, H. Y., Kang, H. S., Yeo, C. D., Kang, H. H., Moon, H. S., & Lee, S. H. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.334 · Cited by 19
“Tumors growing in hypoxic environments are more prone to vigorous growth and metastasis, which are associated with poor prognoses [1,2].”
Background(2003) · PubMed · Cited by 624
(2003) · PubMed · Cited by 167
Metadata
- Authors
- Hockel, M., & Vaupel, P.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Vaupel, P.
- ORCID
- Vaupel, P.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-02-21
- Volume
- 93
- Issue
- 4
- Pages
- 266-276
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2125257427
- Semantic Scholar
- 6c70b98add72efaae8670b5183983be403de59ae
- Cited by
- 2,662
- References
- 159
- Citations by year
- 2026: 46 · 2025: 65 · 2024: 93 · 2023: 134 · 2022: 110 · 2021: 139 · 2020: 149 · 2019: 120 · 2018: 110 · 2017: 148 · 2016: 143 · 2015: 123 · 2014: 114 · 2013: 104 · 2012: 114
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor hypoxia, tissue hypoxia, solid tumors, tumor microcirculation, oxygen partial pressure, tumor progression, treatment resistance, tumor physiology, oxygen diffusion
- MeSH terms
- Animals, Humans, Neoplasms, Oxygen, Predictive Value of Tests, Prognosis, Risk Factors, Cell Hypoxia, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
